课题基金 / 基金详情

Developing animal models to dissociate lysosomal from inflammatory functions of acid sphingomyelinase

Developing animal models to dissociate lysosomal from inflammatory functions of acid sphingomyelinase
开发动物模型以将溶酶体与酸性鞘磷脂酶的炎症功能分离
批准号:
9806440
负责人:
Ashley J. Snider
金额:
$0.14万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-10 至 2019-11-29

项目摘要

项目成果

Ashley J. Snider的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 这项建议的总体目标是表征鞘磷脂中酸性鞘磷脂酶(ASMase)的功能。 体内代谢和病理生物学,并开发更精确的酶替代疗法(ERT) 尼曼-皮克病(NPD)。ASMase催化鞘磷脂(SM)水解为神经酰胺和 磷胆碱。ASMase功能障碍导致A型和B型NPD,一种溶酶体储存障碍 特点是在内溶酶体内积聚鞘磷脂(1)。NPD患者- 出现严重的神经和内脏病理,很少能活到3岁以上(2),而患有 NPD-B通常活到青春期/成年期早期,没有神经体征或症状(3)。 最近,人们对使用aSMase蛋白质或质粒进行重组蛋白质或DNA治疗的努力感兴趣 与非人灵长类动物炎症增加有关(4)。这是因为SMPD1基因 它编码aSMase,产生两种不同的酶--溶酶体鞘磷脂酶(L-SMase)和 分泌型鞘磷脂酶(S-sMase),通过一个共同的蛋白前体的差异运输。我们的 合作者之前已经在细胞中证明了aSMase中的Ser508Ala(S508A)突变 (ASMaseS508A)保留L-sMase活性,但S-sMase(5)缺失。此外,我们已经证明了 在表达aSMaseS508A突变体的细胞中,S-SMase活性的丧失阻止了趋化因子的扩增 炎症细胞因子(6)。先前的工作已经证明,表达aSMase融合蛋白的小鼠 保留L-SMase活性的人表现出对小脑浦肯野细胞层的保护,并被保护在 严重的神经系统疾病观察到aSMase缺陷小鼠(7)。因此,认真测定In S508A突变体的活体功能可能使其发育为有效的ERT(或基因替换),而不存在 发炎效应。 基于这些数据,我们的实验室已经产生了一种新的转基因小鼠模型(GEMM),其中包含 SMPD1基因S508A点突变。这个GEMM,aSMaseS508A,是与Jackson合作生成的 使用CRISPR-CAS9技术的实验室。我们在这些小鼠身上的初步数据显示, 血清中S-SMASE活性。 因此,这项建议的目标具有创新性和重大意义,因为这将是第一次直接 确定SMPD1突变体在体内的作用,确定该突变对鞘磷脂的影响 NPD的代谢、病理和症状。为此,我们提出以下具体目标: 具体目的1.建立aSMaseS508A突变对鞘磷脂体内代谢的影响。 明确aSMaseS508A在体内对NPD病理生物学的影响。
英文摘要
Abstract The overall goal of this proposal is to characterize the function of acid sphingomyelinase (aSMase) in sphingolipid metabolism and pathobiology in vivo and to develop more precise enzyme replacement therapy (ERT) for Niemann-Pick disease (NPD). ASMase catalyzes the hydrolysis of sphingomyelin (SM) to ceramide and phosphocholine. Dysfunction of aSMase results in NPD types A and B, a lysosomal storage disorder characterized by accumulation of sphingomyelin within the endolysosomal compartment (1). Patients with NPD- A develop severe neurologic and visceral pathology and rarely live beyond 3 years of age (2), while patients with NPD-B typically live to adolescence/early adulthood with no manifestation of neurological signs or symptoms (3). Recent interest in the efforts to use aSMase proteins or plasmids for recombinant protein or DNA therapy have been associated with increased inflammation in non-human primates (4). This is because the SMPD1 gene which encodes aSMase, gives rise to two distinct enzymes - lysosomal sphingomyelinase (L-SMase) and secretory sphingomyelinase (S-SMase), via differential trafficking of a common protein precursor. Our collaborators have previously demonstrated in cells that the Ser508Ala (S508A) mutation in aSMase (aSMaseS508A) retains L-SMase activity but is defective in S-SMase (5). Furthermore, we have demonstrated that loss of S-SMase activity in cells expressing the aSMaseS508A mutant prevents chemokine amplification by pro- inflammatory cytokines (6). Previous work has demonstrated that mice expressing an aSMase fusion protein that retained L-SMase activity exhibited protection of the cerebellar Purkinje cell layer and were protected from the severe neurologic disease observed aSMase deficient mice (7). Therefore, careful determination of the in vivo function of the S508A mutant may allow its development as effective ERT (or gene replacement) devoid of inflammatory effects. Building on these data, our lab has generated a novel genetically modified mouse model (GEMM) containing the S508A point-mutation in SMPD1. This GEMM, aSMaseS508A, was generated in collaboration with Jackson Laboratories using CRISPR–Cas9 technology. Our preliminary data in these mice demonstrate complete loss of S-SMase activity in serum. Therefore, the goals of this proposal are innovative and significant as this will be the first study to directly define the role of this SMPD1 variant in vivo, defining the effects of this mutation on sphingolipid metabolism, pathology, and symptoms of NPD. To this end, we propose the following specific aims: Specific Aim 1. Establish the effects of the aSMaseS508A mutations on sphingolipid metabolism in vivo. Specific Aim 2. Define the effects of aSMaseS508A on NPD pathobiology in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role for myeloid acid ceramidase in colon inflammation and cancer
  • 批准号:
    10418031
  • 项目类别:
  • 资助金额:
    $33.21万
  • 财政年份:
    2022
  • 负责人:
    Ashley J. Snider
  • 依托单位:
Role for myeloid acid ceramidase in colon inflammation and cancer
  • 批准号:
    10593982
  • 项目类别:
  • 资助金额:
    $33.21万
  • 财政年份:
    2022
  • 负责人:
    Ashley J. Snider
  • 依托单位:
Sphingolipids, Dietary Fatty Acids, and Intestinal Pathophysiology
  • 批准号:
    10338567
  • 项目类别:
  • 资助金额:
    $33.21万
  • 财政年份:
    2021
  • 负责人:
    Ashley J. Snider
  • 依托单位:
Sphingolipids, Dietary Fatty Acids, and Intestinal Pathophysiology
  • 批准号:
    10532716
  • 项目类别:
  • 资助金额:
    $33.16万
  • 财政年份:
    2021
  • 负责人:
    Ashley J. Snider
  • 依托单位:
海外基金